PHARMACIE BRAUN & PESLA is a French company
founded 32 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in SAINT-AMAND-LES-EAUX (59230),
this company of category PME
shows in 2023 a revenue of 2.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE BRAUN & PESLA (SIREN 392977666)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
2 423 985 €
2 197 094 €
2 142 321 €
1 742 307 €
1 745 042 €
1 832 036 €
1 961 750 €
2 017 271 €
Net income
81 262 €
-83 025 €
257 279 €
328 492 €
92 123 €
101 141 €
80 957 €
79 351 €
115 278 €
EBITDA
N/C
-38 044 €
364 654 €
459 790 €
132 574 €
162 647 €
88 294 €
135 561 €
176 401 €
Net margin
N/C
-3.4%
11.7%
15.3%
5.3%
5.8%
4.4%
4.0%
5.7%
Revenue and income statement
In 2024, PHARMACIE BRAUN & PESLA generates positive net income of 81 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 115 k€ -> 81 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
81 262 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 38%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
38.04%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
58.198%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
176.07
130.191
95.727
78.491
49.448
40.081
57.875
50.955
38.04
Financial autonomy
28.898
33.399
40.402
46.535
55.631
59.147
53.312
53.605
58.198
Repayment capacity
5.78
8.189
130.116
4.254
6.356
1.505
2.801
-10.324
None
Cash flow / Revenue
5.634%
3.614%
0.204%
5.516%
4.483%
15.272%
12.046%
-2.447%
None%
Sector positioning
Debt ratio
38.042024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Good
In 2024, the debt ratio of PHARMACIE BRAUN & PESLA (38.04) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
58.2%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Good
In 2024, the financial autonomy of PHARMACIE BRAUN & PESLA (58.2%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
-10.32 years2023
2022
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Excellent-17 pts over 2 years
In 2023, the repayment capacity of PHARMACIE BRAUN & PESLA (-10.32) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 152.30. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
75.641
79.023
72.801
79.597
203.409
246.405
219.988
168.839
152.301
Interest coverage
16.558
21.258
29.551
12.948
11.867
1.252
1.947
-17.75
None
Sector positioning
Liquidity ratio
152.32024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average-21 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE BRAUN & PESLA (152.30) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
-17.75x2023
2022
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average-17 pts over 2 years
In 2023, the interest coverage of PHARMACIE BRAUN & PESLA (-17.8x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE BRAUN & PESLA
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
261 922 €
226 661 €
172 541 €
201 517 €
205 505 €
189 660 €
410 857 €
493 014 €
0 €
Inventory turnover (days)
39
40
36
38
38
34
53
47
0
Customer payment term (days)
10
10
5
8
5
10
11
8
0
Supplier payment term (days)
55
52
51
38
48
39
46
61
0
Positioning of PHARMACIE BRAUN & PESLA in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE BRAUN & PESLA is estimated at
1 134 477 €
(range 790 032€ - 1 697 243€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
790k€1134k€1697k€
1 134 477 €Range: 790 032€ - 1 697 243€
NAF 5 année 2024
Valuation method used
Net Income Multiple
81 262 €
×
14.0x
=1 134 478 €
Range: 790 032€ - 1 697 243€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE BRAUN & PESLA with other companies in the same sector:
Frequently asked questions about PHARMACIE BRAUN & PESLA
What is the revenue of PHARMACIE BRAUN & PESLA ?
The revenue of PHARMACIE BRAUN & PESLA in 2023 is 2.4 M€.
Is PHARMACIE BRAUN & PESLA profitable?
Yes, PHARMACIE BRAUN & PESLA generated a net profit of 81 k€ in 2024.
Where is the headquarters of PHARMACIE BRAUN & PESLA ?
The headquarters of PHARMACIE BRAUN & PESLA is located in SAINT-AMAND-LES-EAUX (59230), in the department Nord.
Where to find the tax return of PHARMACIE BRAUN & PESLA ?
The tax return of PHARMACIE BRAUN & PESLA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE BRAUN & PESLA operate?
PHARMACIE BRAUN & PESLA operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart